Virus-induced exacerbations in allergic asthmatics. keywords: rhinovirus, exacerbation, allergy, asthma
Conditions
Interventions
Healthy volunteers and allergic asthma patients will be infected by rhinovirus-type 16 (10 TCID50) by spraying the virus into the nasal cavity, leading to mild common cold symptoms. In general, these
Sponsors
Department of Pulmonology of the Academic Medical Center in Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: Allergic asthmatics: 1. Age between 18 and 40 yrs; 2. PC20 to methacholine below 8 mg/ml; 3. Skin-prick test positive to a least one common allergen. Healthy: 1. Age between 18 and 40 yrs; 2. PC20 to methacholine above 16 mg/ml; 3. Skin-prick test negative to all common allergens.
Exclusion criteria
Exclusion criteria: Allergic asthmatics: 1. Current smokers; 2. Ex-smokers with more than 5 packyears; 3. Pre-FEV1 below 80% predicted; 4. Oral or inhaled steroid use; 5. Exacerbations during the past 6 weeks; 6. Underlying pulmonary condition other than asthma; 7. Non-pulmonary underlying conditions that may interfere with the study or that may result in unacceptable risk for the patient (incl. pregnancy); 8. Concomittant drug use (except short-acting bronchodilators); 9. Daily contact with young children (<2yrs). Healthy: 1. Current smokers; 2. Ex-smokers with more than 5 packyears; 3. Pre-FEV1 below 80% predicted; 4. Oral or inhaled steroid use; 5. Underlying pulmonary condition other than asthma; 6. Non-pulmonary underlying conditions that may interfere with the study or that may result in unacceptable risk for the patient (incl. pregnancy); 7. Concomittant drug use (except short-acting bronchodilators); 8. Daily contact with young children (<2yrs).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Common cold questionnaire; 2. Asthma symptom score; 3. FEV1; 4. PC20 methacholine; 5. Inflammatory cell numbers; 6. Indoleamine 2,3-dioxygenase expression; 7. Apoptotic markers. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Exhaled NO; 2. ENose measurement; 3. Coagulation parameters. | — |
Contacts
Public ContactPeter J. Sterk
Dept. Pulmonology, F5-259 Academic Medical Center University of Amsterdam P.O. Box 22700
Outcome results
None listed